Download PDF
Diabetes aktuell 2016; 14(01): 49-50
DOI: 10.1055/s-0041-110922
Forum der Industrie
Georg Thieme Verlag KG Stuttgart · New York

Positive Effekte auf den Insulinbedarf – Überzeugende Daten zu Sitagliptin

Further Information

Publication History

Publication Date:
23 March 2016 (online)

Also available at
   Permissions and Reprints

Mit ihrer Forderung nach kardiovaskulären Endpunktstudien haben die US-amerikanische und die europäische Zulassungsbehörde die kardiovaskuläre Sicherheit antidiabetischer Therapiestrategien in den Fokus des Interesses gerückt [ 1 ], [ 2 ]. Dem hat der Dipeptidylpeptidase-4-Inhibitor (DPP-4-Hemmer) Sitagliptin mit der Präsentation der TECOS[ 1 ]-Studiendaten [ 3 ] Anfang Juni dieses Jahres auf dem Kongress der „American Diabetes Association“ Rechnung getragen – und seine kardiovaskuläre Sicherheit belegt.

 

  • Literatur

  • 1 Department of Health and Human Services, Food and Drug Administartion, Center for Drug Evaluationand Research. Guidance for industry: diabetes mellitus – evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. 12/2008 www.fda.fov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071627
    Google Scholar
  • 2 European Medicine Agency, Committee for Medicinal Products for Human Use, Guideline on clinical investigation of medicinal products in the treatment of diabetes mellitus. 01/2010 www.ema.europa.eu/docs/en_GB/dicument_library/Scientific_guideline/2010/02/WC500073570.pdf
    Google Scholar
  • 3 Green J, Bethel MA, Armstrong PW et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med 2015; 373: 586
    CrossrefGoogle Scholar
  • 4 Scirica BM, Ghatt DL, Braunwald E et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013; 369: 1317-1326
    CrossrefGoogle Scholar
  • 5 White WB, Cannon CP, Heller SR et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 2013; 369: 1327-1335
    CrossrefGoogle Scholar
  • 6 Nationale Versorgungsleitlinie Therapie des Typ-2-Diabetes, August 2013
  • 7 Derosa G, D’Angelo A, Maffioli P. Sitagliptin in type 2 diabetes mellitus: efficacy after five years of therapy. Pharmacol Res 2015; 100: 127-134
    CrossrefGoogle Scholar
  • 8 Inzucchi SE, Bergenstal RM, Buse JB et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American diabetes Association (ADA) and the European association for the Study of Diabetes (EASD). Diabetes Care 2012; 35: 1364-1379
    CrossrefPubMedGoogle Scholar
  • 9 Mathieu C, Sankar R, Lorber D et al. A randomized clinical trial to evaluate the efficacy and safety of co-administration of sitagliptin with intensively titrated insulin glarigne. Diabetes Ther 2015; 6: 127-142
    CrossrefPubMedGoogle Scholar
  • 10 Riddle MC, Schneider J. Beginning insulin treatment of obese patients with evening 70/30 insulin plus glimepiride versus insulin alone. Diabetes Care 1998; 21: 1052-1057
    CrossrefGoogle Scholar
  • 11 Schwartz S, Raskin P, Fonseca V, Graveline JF. Effect of troglitazone in insulin-treated patients with type III diabetes mellitus. N Engl J Med 1998; 338: 861-866
    CrossrefGoogle Scholar
  • 12 Yki-Jarvinen H, Rosenstock J, Duran-Garcia S et al. Effects of adding linagliptin to basal insulin regimen for inadequately controlled type 2 diabetes: a ≥ 52-week randomized, double-blind study. Diabetes Care 2013; 36: 3875-3881
    CrossrefGoogle Scholar